Sondel PM - Search Results

1

Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19.

Ascierto PA, Fox BA, Urba WJ, Anderson AC, Atkins MB, Borden EC, Brahmer JR, Butterfield LH, Cesano A, Chen DC, de Gruijl TD, Dillman RO, Drake CG, Emens LA, Gajewski TF, Gulley JL, Stephen Hodi FJ, Hwu P, Kaufman D, Kaufman HL, Lotze MT, McNeel DG, Margolin KM, Marincola FM, Mastrangelo MJ, Maus MV, Parkinson DR, Romero PJ, Sondel PM, Spranger S, Sznol M, Weiner GJ, Wigginton JM, Weber JS. Ascierto PA, et al. Among authors: sondel pm. J Immunother Cancer. 2020 Apr;8(1):e000878. doi: 10.1136/jitc-2020-000878. J Immunother Cancer. 2020. PMID: 32300051 Free PMC article. No abstract available.

2

Effects of interleukin-2 (IL-2) on human plasma lipid, lipoprotein, and C-reactive protein.

Rosenzweig IB, Wiebe DA, Hank JA, Albers JJ, Adolphson JL, Borden E, Shrago ES, Sondel PM. Rosenzweig IB, et al. Among authors: sondel pm. Biotherapy. 1990;2(3):193-8. doi: 10.1007/BF02173519. Biotherapy. 1990. PMID: 1698421 Clinical Trial.

3

Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS.

Brown RR, Ozaki Y, Datta SP, Borden EC, Sondel PM, Malone DG. Brown RR, et al. Among authors: sondel pm. Adv Exp Med Biol. 1991;294:425-35. doi: 10.1007/978-1-4684-5952-4_39. Adv Exp Med Biol. 1991. PMID: 1722946 Review.

4

Immunological effects of levamisole in vitro.

Schiller JH, Lindstrom M, Witt PL, Hank JA, Mahvi D, Wagner RJ, Sondel P, Borden EC. Schiller JH, et al. J Immunother (1991). 1991 Oct;10(5):297-306. doi: 10.1097/00002371-199110000-00001. J Immunother (1991). 1991. PMID: 1790137

5

The appearance of hypodense eosinophils during interleukin-2 treatment.

Sedgwick JB, Frick WE, Sondel PM, Hank JA, Borden E, Busse WW. Sedgwick JB, et al. Among authors: sondel pm. J Allergy Clin Immunol. 1990 Mar;85(3):557-66. doi: 10.1016/0091-6749(90)90093-j. J Allergy Clin Immunol. 1990. PMID: 2312991

6

Lymphokines and cytokines as cancer treatment. Immunotherapy realized.

Borden EC, Sondel PM. Borden EC, et al. Among authors: sondel pm. Cancer. 1990 Feb 1;65(3 Suppl):800-14. doi: 10.1002/1097-0142(19900201)65:3+<800::aid-cncr2820651328>3.0.co;2-y. Cancer. 1990. PMID: 2406003 Review.

7

Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures.

Carlin JM, Borden EC, Sondel PM, Byrne GI. Carlin JM, et al. Among authors: sondel pm. J Immunol. 1987 Oct 1;139(7):2414-8. J Immunol. 1987. PMID: 2443564

8

Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes.

Carlin JM, Borden EC, Sondel PM, Byrne GI. Carlin JM, et al. Among authors: sondel pm. J Leukoc Biol. 1989 Jan;45(1):29-34. doi: 10.1002/jlb.45.1.29. J Leukoc Biol. 1989. PMID: 2463322

9

Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation.

Voss SD, Hank JA, Nobis CA, Fisch P, Sosman JA, Sondel PM. Voss SD, et al. Among authors: sondel pm. Cancer Immunol Immunother. 1989;29(4):261-9. doi: 10.1007/BF00199214. Cancer Immunol Immunother. 1989. PMID: 2787694 Free PMC article.

10

Clinical and immunological effects of human recombinant interleukin-2 given by repetitive weekly infusion to normal dogs.

Helfand SC, Soergel SA, MacWilliams PS, Hank JA, Sondel PM. Helfand SC, et al. Among authors: sondel pm. Cancer Immunol Immunother. 1994 Aug;39(2):84-92. doi: 10.1007/BF01525313. Cancer Immunol Immunother. 1994. PMID: 8044833 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

382 results

Search Page

Filters